NCT07476001 2026-03-17
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
13 trialsNCT06193486 2026-02-02
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06866938 2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06568562 2025-12-09
PRO-XL
University of Utah
Phase 2 Recruiting
NCT06029998 2025-11-28
BORXPTEN
University of Utah
Phase 2 Recruiting
NCT06100705 2025-11-04
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
Phase 2 Recruiting
NCT05603559 2025-10-03
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT06401980 2025-08-14
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting
NCT06480110 2025-04-13
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
Phase 1/2 Recruiting
NCT05116579 2024-09-05
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Sun Yat-sen University
Recruiting
NCT06529549 2024-07-31
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
Sun Yat-sen University
Recruiting
NCT05613738 2024-07-10
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting